Details for Patent: 8,840,924
✉ Email this page to a colleague
Which drugs does patent 8,840,924 protect, and when does it expire?
Patent 8,840,924 protects ADZENYS XR-ODT and COTEMPLA XR-ODT and is included in two NDAs.
Summary for Patent: 8,840,924
| Title: | Compositions and methods of making rapidly dissolving ionically masked formulations |
| Abstract: | The present invention includes compositions and methods for reduce the taste of the drug in the drug resin complex. The composition may include one or more drug-resin complexes and a highly compressible, free-flowing pharmaceutical excipient. The resin is present in an amount effective to reduce the taste of the drug in the drug resin complex relative to an otherwise identical pharmaceutical composition without the resin; and wherein the highly compressible, free-flowing pharmaceutical excipient causes release of the drug-resin complex in the mouth. |
| Inventor(s): | Tengler; Mark (Colleyville, TX), McMahen; Russell (Flower Mound, TX) |
| Assignee: | NEOS Therapeutics, LP (Grand Prairie, TX) |
| Application Number: | 12/717,251 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,840,924 |
|
Patent Claim Types: see list of patent claims | Composition; Delivery; |
More… ↓ |
Drugs Protected by US Patent 8,840,924
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-001 | Jan 27, 2016 | RX | Yes | No | 8,840,924 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-002 | Jan 27, 2016 | RX | Yes | No | 8,840,924 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-003 | Jan 27, 2016 | RX | Yes | No | 8,840,924 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-004 | Jan 27, 2016 | RX | Yes | No | 8,840,924 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-005 | Jan 27, 2016 | RX | Yes | No | 8,840,924 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
